{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Affinity",
    "query": {
      "intervention": "Affinity"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 139,
    "total_pages": 14,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Affinity&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-11T21:24:43.706Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03335670",
      "title": "Gallium 68 Pentixafor in Patients With Neuroendocrine Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Neuroendocrine Tumors"
      ],
      "interventions": [
        {
          "name": "[68Ga]Pentixafor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yusuf Menda",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2017-11-03",
      "completion_date": "2030-06-30",
      "has_results": false,
      "last_update_posted_date": "2025-07-14",
      "last_synced_at": "2026-09-11T21:24:43.706Z",
      "location_count": 1,
      "location_summary": "Iowa City, Iowa",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03335670"
    },
    {
      "nct_id": "NCT06842030",
      "title": "Feasibility Trial of Darwin OncoTreat and OncoTarget Precision Medicine Testing",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Personalized Medicine",
        "Oligometastatic Disease",
        "Feasibility"
      ],
      "interventions": [
        {
          "name": "Darwin OncoTarget and OncoTreat",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Good Samaritan Hospital Medical Center, New York",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2025-03-10",
      "completion_date": "2027-04-10",
      "has_results": false,
      "last_update_posted_date": "2025-02-24",
      "last_synced_at": "2026-09-11T21:24:43.706Z",
      "location_count": 1,
      "location_summary": "West Islip, New York",
      "locations": [
        {
          "city": "West Islip",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06842030"
    },
    {
      "nct_id": "NCT06433635",
      "title": "Sequential Multiple Assignment Randomized Trial for Bipolar Depression",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Bipolar I Disorder",
        "Depression"
      ],
      "interventions": [
        {
          "name": "Cariprazine",
          "type": "DRUG"
        },
        {
          "name": "Aripiprazole/Escitalopram combination",
          "type": "DRUG"
        },
        {
          "name": "Quetiapine",
          "type": "DRUG"
        },
        {
          "name": "Lurasidone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 2726,
      "start_date": "2024-10-01",
      "completion_date": "2030-02-28",
      "has_results": false,
      "last_update_posted_date": "2025-12-16",
      "last_synced_at": "2026-09-11T21:24:43.706Z",
      "location_count": 17,
      "location_summary": "Birmingham, Alabama • Bloomington, Indiana • Baltimore, Maryland + 13 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Bloomington",
          "state": "Indiana"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Belmont",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06433635"
    },
    {
      "nct_id": "NCT03853317",
      "title": "QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint Therapy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Merkel Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Avelumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "N-803",
          "type": "BIOLOGICAL"
        },
        {
          "name": "haNK™",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "ImmunityBio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2020-02-19",
      "completion_date": "2022-09-19",
      "has_results": true,
      "last_update_posted_date": "2024-08-09",
      "last_synced_at": "2026-09-11T21:24:43.706Z",
      "location_count": 5,
      "location_summary": "San Francisco, California • Miami, Florida • St Louis, Missouri + 1 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03853317"
    },
    {
      "nct_id": "NCT05756426",
      "title": "Consortium for Optimized Integration of Bio-Artificial Blood Components for Adaptive Resuscitation Therapy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hemorrhage",
        "Hemodynamic Instability"
      ],
      "interventions": [
        {
          "name": "Prospective",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Maryland, Baltimore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "88 Years",
        "sex": "ALL",
        "summary": "18 Years to 88 Years"
      },
      "enrollment_count": 250,
      "start_date": "2023-04-13",
      "completion_date": "2029-01-30",
      "has_results": false,
      "last_update_posted_date": "2026-08-25",
      "last_synced_at": "2026-09-11T21:24:43.706Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05756426"
    },
    {
      "nct_id": "NCT03900026",
      "title": "Effect of Evolocumab on Saphenous Vein Graft Patency Following Coronary Artery Bypass Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Coronary Artery Bypass Graft Surgery",
        "Atherosclerosis",
        "Vein Occlusion"
      ],
      "interventions": [
        {
          "name": "Evolocumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Unity Health Toronto",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 782,
      "start_date": "2019-05-30",
      "completion_date": "2025-01-30",
      "has_results": false,
      "last_update_posted_date": "2025-08-29",
      "last_synced_at": "2026-09-11T21:24:43.706Z",
      "location_count": 5,
      "location_summary": "San Francisco, California • Jacksonville, Florida • Portland, Maine + 2 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Portland",
          "state": "Maine"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03900026"
    },
    {
      "nct_id": "NCT01520922",
      "title": "Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Lymphocytic Leukemia (CLL)",
        "Leukaemia, Lymphocytic, Chronic"
      ],
      "interventions": [
        {
          "name": "Ofatumumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Bendamustine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 99,
      "start_date": "2012-03",
      "completion_date": "2015-11",
      "has_results": true,
      "last_update_posted_date": "2017-01-19",
      "last_synced_at": "2026-09-11T21:24:43.706Z",
      "location_count": 6,
      "location_summary": "Tuscon, Arizona • Aurora, Colorado • Fort Myers, Florida + 3 more",
      "locations": [
        {
          "city": "Tuscon",
          "state": "Arizona"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01520922"
    },
    {
      "nct_id": "NCT05156320",
      "title": "Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or Risdiplam",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Spinal Muscular Atrophy",
        "Spinal Muscular Atrophy Type 3",
        "Spinal Muscular Atrophy Type 2",
        "SMA",
        "Neuromuscular Diseases",
        "Muscular Atrophy",
        "Atrophy",
        "Muscular Atrophy, Spinal",
        "Neuromuscular Manifestations",
        "Anti-myostatin"
      ],
      "interventions": [
        {
          "name": "Apitegromab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Scholar Rock, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "2 Years to 21 Years"
      },
      "enrollment_count": 188,
      "start_date": "2022-04-14",
      "completion_date": "2024-12-18",
      "has_results": false,
      "last_update_posted_date": "2026-01-22",
      "last_synced_at": "2026-09-11T21:24:43.706Z",
      "location_count": 26,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 23 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05156320"
    },
    {
      "nct_id": "NCT02858076",
      "title": "Anti-VEGF vs. Prompt Vitrectomy for VH From PDR",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Proliferative Diabetic Retinopathy",
        "Vitreous Hemorrhage"
      ],
      "interventions": [
        {
          "name": "2-mg Intravitreous Aflibercept Injection",
          "type": "DRUG"
        },
        {
          "name": "Prompt Vitrectomy Plus Panretinal Photocoagulation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Jaeb Center for Health Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 205,
      "start_date": "2016-11",
      "completion_date": "2020-01",
      "has_results": true,
      "last_update_posted_date": "2021-04-20",
      "last_synced_at": "2026-09-11T21:24:43.706Z",
      "location_count": 60,
      "location_summary": "Campbell, California • Glendale, California • Huntington Beach, California + 50 more",
      "locations": [
        {
          "city": "Campbell",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Porterville",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02858076"
    },
    {
      "nct_id": "NCT05564429",
      "title": "[18F]SF12051 for Imaging the 18-kDa Translocator Protein (TSPO) in Brain and Whole Body of Healthy Subjects",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "18F-SF12051",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Mental Health (NIMH)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 10,
      "start_date": "2023-02-02",
      "completion_date": "2024-01-30",
      "has_results": true,
      "last_update_posted_date": "2024-07-09",
      "last_synced_at": "2026-09-11T21:24:43.706Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05564429"
    }
  ]
}